Signal A $200 million public-private partnership was announced in March 2026 to fund further trials
Summary
The chapter reads a $200 million public-private partnership announced in March 2026 to fund further trials as evidence that personalized cancer vaccines have moved past proof of concept.
Classification
Main topicWelfare & Health
Region menusGlobal
Occurrencescope:country · geo_region:north_america · country:US
Impactscope:global
Time horizon0-3 years (2026-07-26)
Last updated2026-07-29 04:49:52
Evidence 1
- Top 10 Emerging Technologies of 2026 World Economic Forum (in collaboration with Frontiers) page=24;section=7 Personalized mRNA cancer vaccines 2026-06 accessed 2026-07-26
Part of trends 1
Directly linked issues 0
No objects.
Relation types: supports
Public id: fm-fb0ff0f7f405